APOPHARMA
Desconocido
FAIR-PARK-II: Conservative iron chelation as a disease modifying strategy in Parkinson s disease a multicentric...
APOPHARMA INC CORP
participó en un
H2020:
H2020-PHC-2014-2015
Parkinson’s disease (PD) is a major, chronic, non-communicable disease and the 2nd most frequent neurodegenerative disorder worldwide. Exces...
2015-04-14 - 2021-10-31 | Financiado
2015-04-14 - 2021-10-31 | Financiado
TIRCON: Treat Iron Related Childhood Onset Neurodegeneration
APOPHARMA INC CORP
participó en un
FP7:
Neurodegeneration with brain iron accumulation (NBIA) is a heterogeneous group of rare hereditary neurodegenerative disorders characterized...
Financiado
Financiado
DEEP: DEferiprone Evaluation in Paediatrics
APOPHARMA INC CORP
participó en un
FP7:
β-thalassaemia major is one of the most severe forms of chronic congenital anaemia. The recommended treatment consists in regular blood tran...
Financiado
Financiado
* No se disponen de datos de la empresa actual.